未知股票 BCLI 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 1103.48万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Brainstorm Cell Therapeutics Secures New Convertible Debt Financing
Brainstorm Cell Therapeutics ( ($BCLI) ) has provided an announcement. On Decem...
01-10 06:06
BrainStorm Cell Therapeutics is trading lower after receiving a delisting notice from Nasdaq effective July 18, 2025.
BrainStorm Cell Therapeutics is trading lower after receiving a delisting notic...
2025-07-18 04:42
Brainstorm Cell Therapeutics Files Prospectus For Offer & Sale Of Up To 2.8M Shares Of Common Stock By Selling Stockholder
https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm
2025-06-26 04:47
BrainStorm Announces New Survival Data From Expanded Access Program Of NurOwn In ALS; 90% Of Participants Survived More Than Five Yers From Onset Of ALS Symptoms
Key findings include:90% of participants (9/10) survived more than five years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS survive beyond five
2025-06-16 20:31
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Longevity Health Holdings (NASDAQ:XAGE) shares moved upwards by 55.5% ...
2025-05-22 05:06
Brainstorm Cell Therapeutics Reports Q1 2025 Financials
Brainstorm Cell Therapeutics ( ($BCLI) ) has released its Q1 earnings. Here is ...
2025-05-20 11:54
Market-Moving News for May 19th
BCLI: 120% | BrainStorm Cell Therapeutics shares are trading higher after the company received FDA clearance to initiate its Phase 3b trial of NurOwn for the treatment of ALS. NVAX: 28% | Novavax Wins
2025-05-19 19:16
BrainStorm Cell Therapeutics shares are trading higher after the company received FDA clearance to initiate its Phase 3b trial of NurOwn for the treatment of ALS.
BrainStorm Cell Therapeutics shares are trading higher after the company receiv...
2025-05-19 19:04
Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.97) by 53.61 percent. This is a 40 percent increase over losses of $(0.75) per share from the
2025-05-16 04:27
BrainStorm Cell Therapeutics Q4 2024 Earnings Preview
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is scheduled to announce Q4 earnings results on Monday, March 31st, before market open. The consensus EPS Estimate is -$0.27 (+32.5% Y/Y). Over the last 1 ye...
2025-03-29 00:45
